| Identification | Back Directory | [Name]
Hexanoic acid, 6-(nitrooxy)-, (1S,2E)-3-[(1R,2R,3S,5R)-2-[(2Z)-7-(ethylamino)-7-oxo-2-hepten-1-yl]-3,5-dihydroxycyclopentyl]-1-(2-phenylethyl)-2-propen-1-yl ester | [CAS]
1194396-71-8 | [Synonyms]
NCX 470
15-(6-nitroxyhexanoyl)-17-phenyl trinor Prostaglandin F2α
Hexanoic acid, 6-(nitrooxy)-, (1S,2E)-3-[(1R,2R,3S,5R)-2-[(2Z)-7-(ethylamino)-7-oxo-2-hepten-1-yl]-3,5-dihydroxycyclopentyl]-1-(2-phenylethyl)-2-propen-1-yl ester | [Molecular Formula]
C31H46N2O8 | [MOL File]
1194396-71-8.mol | [Molecular Weight]
574.71 |
| Chemical Properties | Back Directory | [Boiling point ]
739.4±60.0 °C(Predicted) | [density ]
1.180±0.06 g/cm3(Predicted) | [storage temp. ]
-20°C | [solubility ]
DMSO: 10 mg/ml,Ethanol: 10 mg/ml | [form ]
Oil | [pka]
14.53±0.70(Predicted) | [color ]
Colorless to light yellow |
| Hazard Information | Back Directory | [Uses]
Bimatoprost grenod (NCX 470) is a second-generation nitric oxide (NO)-donating prostaglandin analogue. Bimatoprost grenod effectively lowers intraocular pressure (IOP) in animal models of ocular hypertension and glaucoma by activating bimatoprost-mediated uveoscleral outflow and NO mediated conventional outflow. Bimatoprost grenod can be used for the research of cular hypertension and glaucoma[1][2]. | [Biological Activity]
15-(6-nitroxyhexanoyl)-17-phenyl trinor Prostaglandin F2α (15-(6-nitroxyhexanoyl)-17-phenyl trinor PGF2α) is a nitric oxide-donating derivative of 17-phenyl trinor PGF2α .1 It increases cGMP levels in rabbit aqueous humor and iris ciliary body when topically administered at a concentration of 0.042%. Topical administration of 15-(6-nitroxylhexanoyl)-17-phenyl trinor PGF2α (0.14%) reduces intraocular hypertension (IOP) in a rabbit model of hypertonic saline-induced transient ocular pressure. It also reduces IOP in a cynomolgus monkey model of laser-induced ocular hypertension when administered topically at a concentration of 0.042%. | [in vivo]
Bimatoprost grenod shows a better intraocular pressure-lowering efficacy than that of equimolar doses of bimatoprost in well-established animal models of glaucoma and ocular hypertension[1].
Bimatoprost grenod (0.14% 30 μL; instillation; once) reduces IOP in transient ocular hypertensive rabbits[2].
Bimatoprost grenod (0.042% 30 μL; instillation; once) is more effective than equimolar bimatoprost in cynomolgus monkeys with laser-induced ocular hypertension (OHT-monkeys), and normotensive dogs (ONT-dogs) at 18 hours post dosing[2]. | Animal Model: | New Zealand white rabbits with 0.1 mL 5% sodium chloride solution injection[2] | | Dosage: | 0.14% | | Administration: | Instillation; 0.14% 30 μL; once | | Result: | Significantly blunted the IOP rise throughout the experimental period in transiently ocular hypertensive New Zealand
white rabbits.
|
| [storage]
-20°C | [References]
1.Impagnatiello, F., Toris, C.B., Batugo, M., et al.Intraocular pressure-lowering activity of NCX 470, a novel nitric oxide-donating bimatoprost in preclinical modelsInvest. Ophthalmol. Vis. Sci.56(11)6558-6564(2015)
|
|
| Company Name: |
ChemeGen
|
| Tel: |
18818260767 |
| Website: |
https://www.chemegen.com |
|